Apr 2014 $3 M Private placement after listing $2 to $10 million 17
Provectus Pharmaceuticals Inc.: Private sale, Apr 2014 × Investors in this round 17 investors had bought by the notice of Apr 17, 2014: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $5 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $334,587
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Eric A. Wachter · Executive Officer · Chief Technology Officer H. Craig Dees · Executive Officer, Director · CEO Peter R. Culpepper · Executive Officer · CFO, COO, CAO Timothy C. Scott · Executive Officer, Director · President Alfred E. Smith IV · Director Jan C. Koe · Director Kelly M. McMasters · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New Jersey Sold in CT, FL, IL, NY, OH, TX, VA, and outside the US Remarks in the notice On fees: “Placement agent will receive: (i) 10% commission of the aggregate purchase price of the securities sold; (ii) 3% of the offering proceeds as non-accountable expenses; and (iii) cashless warrants equal to 15% of total units sold with $2.50 exercise price.”Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 17, 2014. Read the notice at the SEC .
equity, options SEC Mar 2013 $8 M Private placement after listing $2 to $10 million 67
Provectus Pharmaceuticals Inc.: Private sale, Mar 2013 × Investors in this round 67 investors had bought by the notice of Sep 26, 2013: 67 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $16 M offered; $8 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $1,600,000
Finders' fees none
Paid to its own people $1,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Nevada People named in the notice Eric A. Wachter · Executive Officer · Chief Technology Officer H. Craig Dees · Executive Officer, Director · CEO Peter R. Culpepper · Executive Officer · CFO, COO, CAO Timothy C. Scott · Executive Officer, Director · President Alfred E. Smith IV · Director Jan C. Koe · Director Kelly M. McMasters · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New Jersey Sold in CT, FL, IL, KY, MN, NC, NJ, NY, OH, PA, TN, TX, VA, WI, and outside the US Maxim Group LLC (CRD 1207087) · New York, New York Sold in AK, AZ, CA, CO, CT, FL, GA, HI, IL, IN, LA, MA, MD, MI, MO, NC, NJ, NY, OH, OK, PA, PR, SC, TN, TX, VA, VT, WA, WI Remarks in the notice On fees: “Placement agent will receive a 10% commission plus warrants to purchase 10% of the aggregate number of shares of common stock issued in the offering, with an exercise price of $1.00 per share.”Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 26, 2013. Read the notice at the SEC .
equity, options SEC Feb 2013 $3 M Private placement after listing $2 to $10 million 3
Provectus Pharmaceuticals Inc.: Private sale, Feb 2013 × Investors in this round 3 investors had bought by the notice of Mar 8, 2013: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Eris A. Wachter · Executive Officer · Chief Technology Officer H. Craig Dees · Executive Officer · CEO Peter R. Culpepper · Promoter, Executive Officer · CFO, COO, CAO Timothy C. Scott · Executive Officer, Director · President Alfred E. Smith IV · Director Jan C. Koe · Director Kelly M. McMasters · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 8, 2013. Read the notice at the SEC .
equity, options SEC Nov 2012 $2 M Private placement after listing $2 to $10 million 5
Provectus Pharmaceuticals Inc.: Private sale, Nov 2012 × Investors in this round 5 investors had bought by the notice of Nov 19, 2012: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $5 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $500,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Nevada People named in the notice Eric A. Wachter · Executive Officer · Chief Technology Officer H. Craig Dees · Executive Officer, Director · CEO Peter R. Culpepper · Executive Officer · CFO, COO, CAO Timothy C. Scott · Executive Officer, Director · President Alfred E. Smith IV · Director Jan C. Koe · Director Kelly M. McMasters · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New Jersey Sold in FL, TN, TX Remarks in the notice On fees: “Placement agent will receive warrants to purchase up to 10% of the aggregate number of shares of common stock issued in the Offering, with an exercise price of $1.00 per share, plus a 10% commission (5% commission for sales to the issuer's affiliates).”Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 19, 2012. Read the notice at the SEC .
equity, options SEC Mar 2012 $2 M Private placement after listing $2 to $10 million 16
Provectus Pharmaceuticals Inc.: Private sale, Mar 2012 × Investors in this round 16 investors had bought by the notice of Aug 3, 2012: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $5 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Alfred E. Smith IV · Director, Executive Officer · Vice President Eric A. Wachter · Executive Officer · Chief Technology Officer H. Craig Dees · Executive Officer, Director · CEO Peter R. Culpepper · Executive Officer · CFO, COO, CAO Timothy C. Scott · Executive Officer, Director · President Jan C. Koe · Director Kelly M. McMasters · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New Jersey Sold in FL, KY, NJ, NY, OH, TX, WI, and outside the US Remarks in the notice On fees: “Company will the issue placement agent warrants to purchase up to 20% of aggregate amount of shares issued at exercise price of $1.12 per share for five years”Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 3, 2012. Read the notice at the SEC .
equity, options SEC Apr 2011 $5 M No. 5 $2 to $10 million 26
Provectus Pharmaceuticals Inc.: Raise no. 5, Apr 2011 × Investors in this round 26 investors had bought by the notice of May 5, 2011: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Craig H. Dees · Executive Officer, Director Peter R. Culpepper · Executive Officer Timothy C. Scott · Executive Officer, Director Eric A. Wachter · Director Kelly M. McMasters · Director Stuart R. Fuchs · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, New Jersey Sold in CT, DC, FL, IL, MI, MN, NJ, NY, OH, OR, PA, TX, VA Remarks in the notice On fees: “Network 1 Financial Securities, Inc. will receive, as a sales commission, warrants to purchase up to 20% of the common stock issued at closing to investors solicited by such placement agent.”Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed May 5, 2011. Read the notice at the SEC .
equity, options SEC Mar 2010 $1 M No. 4 Under $2 million 14
Provectus Pharmaceuticals Inc.: Raise no. 4, Mar 2010 × Investors in this round 14 investors had bought by the notice of Apr 6, 2010: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $127,190
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Nevada People named in the notice Craig H. Dees · Executive Officer, Director Peter R. Culpepper · Executive Officer Timothy C. Scott · Executive Officer, Director Eric A. Wachter · Director Kelly M. McMasters · Director Stuart R. Fuchs · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round William David Vellon (CRD 1954258) · broker-dealer Brewer Financial Services, LLC (CRD 132558) · Chicago, Il Sold in no state named Asher Wolmark (CRD 2064857) · broker-dealer Brewer Financial Services, LLC (CRD 132558) · Chicago, Il Sold in no state named Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 6, 2010. Read the notice at the SEC .
equity, options SEC Mar 2010 $8 M No. 3 $2 to $10 million 36
Provectus Pharmaceuticals Inc.: Raise no. 3, Mar 2010 × Investors in this round 36 investors had bought by the notice of Mar 24, 2010: 36 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $10 M offered; $2 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $793,750
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Nevada People named in the notice Craig H. Dees · Executive Officer, Director Peter R. Culpepper · Executive Officer Timothy C. Scott · Executive Officer, Director Eric A. Wachter · Director Kelly M. McMasters · Director Stuart R. Fuchs · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · broker-dealer 0 (CRD 0) · New York, Ny Sold in no state named Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 24, 2010. Read the notice at the SEC .
equity, options SEC May 2009 $3 M No. 2 $2 to $10 million 47
Provectus Pharmaceuticals Inc.: Raise no. 2, May 2009 × Investors in this round 47 investors had bought by the notice of Jun 30, 2009: 47 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $271,200
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Nevada People named in the notice Eric A. Wachter · Executive Officer, Director H. Craig Dees · Executive Officer, Director Peter R. Culpepper · Executive Officer Timothy C. Scott · Executive Officer, Director Kelly M. McMasters · Director Stuart Fuchs · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities Inc. (CRD 13577) · Red Bank, Nj Sold in no state named Maxim Group LLC (CRD 120708) · New York, Ny Sold in no state named Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 30, 2009. Read the notice at the SEC .
equity, options SEC Apr 2009 $8 M No. 1 $2 to $10 million 90
Provectus Pharmaceuticals Inc.: Raise no. 1, Apr 2009 × Investors in this round 90 investors had bought by the notice of Mar 26, 2010: 90 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Provectus Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $10 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $761,333
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Nevada People named in the notice Craig H. Dees · Executive Officer, Director Eric A. Wachter · Executive Officer, Director Peter R. Culpepper · Executive Officer Timothy C. Scott · Executive Officer, Director Kelly M. McMasters · Director Stuart R. Fuchs · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Network 1 Financial Securities, Inc. (CRD 13577) · Red Bank, Nj Sold in no state named Maxim Group LLC (CRD 120708) · New York, Ny Sold in no state named Remarks in the notice On fees: “Commission as shown does not include a non-accountable expense allowance of 3% of gross proceeds and common stock equal to 10% of the total number of shares of common stock issued at closing.”Signed by Peter R. Culpepper, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 26, 2010. Read the notice at the SEC .
equity, options SEC